Advanced therapeutic and prophylactic strategies for Epstein–Barr virus infection in immunocompromised patients

References

• Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet15, 702–703 (1964).
   Web of Science ®Google Scholar
• Okano M. Haematological associations of Epstein–Barr virus infection. Bailliere’s Best Pract. Res. Clin. Haematol.13, 199–214 (2000).
   PubMed Web of Science ®Google Scholar
• Henle G, Henle W. Immunofluorescence in cells derived from Burkitt’s lymphoma. J. Bacteriol.91, 1248–1256 (1966).
   PubMed Web of Science ®Google Scholar
• Henle G, Henle W, Diehl V. Relation to Burkitt’s tumor-associated herpes type virus to infectious mononucleosis. Proc. Natl Acad. Sci. USA59, 94–101 (1968).
   PubMed Web of Science ®Google Scholar
• Evans AS, Niderman JC, McCollum RW. Seroepidemiologic studies of infectious mononucleosis with EB virus. N. Engl. J. Med.279, 1121–1127 (1968).
   PubMed Web of Science ®Google Scholar
• Old LJ, Boyse EA, Oettgen HF et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt’s lymphoma cells. Proc. Natl Acad. Sci. USA56, 1699–1704 (1966).
   PubMed Web of Science ®Google Scholar
• zur Hausen H, Schulte-Holthausen H, Klein G et al. EB-virus DNA in biopsies of Burkitt’s tumors and anaplastic carcinomas of the nasopharynx. Nature228, 1056–1057 (1970).
   PubMed Web of Science ®Google Scholar
• Purtilo DT, Cassel CK, Yang JPS et al. X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet1(7913), 935–941 (1975).
   PubMed Web of Science ®Google Scholar
• Chapel H, Geha R, Rosen F. IUIS (Primary Immunodeficiencies) Classification Committee. Primary immunodeficiency diseases: an update. Clin. Exp. Immunol.132, 9–15 (2003).
   PubMed Web of Science ®Google Scholar
• Joncas J, LaPointe N, Gervais F, Leyritz M. Unusual prevalence of Epstein–Barr early antigen (EBV-EA) antibody in ataxia–telangiectasia. J. Immunol.119, 1857–1859 (1977).
   PubMed Web of Science ®Google Scholar
• Saemundsen AK, Berkel AI, Henle W et al. Epstein–Barr virus carrying lymphoma in a patient with ataxia telangiectasia. Br. Med. J.282, 425–427 (1981).
   PubMed Web of Science ®Google Scholar
• Okano M, Mizuno F, Osato T, Takahashi Y, Sakiyama Y, Matsumoto S. Wiskott–Aldrich syndrome and Epstein–Barr virus-induced lymphoproliferation. Lancet2(8408), 933–934 (1984).
   PubMedGoogle Scholar
• Nakanishi M, Kikuta H, Tomizawa K et al. Distinct clonotypic Epstein–Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott–Aldrich syndrome. Cancer72, 1376–1381 (1993).
   PubMed Web of Science ®Google Scholar
• Crawford DH, Thomas JA, Janossy G et al. Epstein–Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet1(8182), 1355–1356 (1980).
   PubMed Web of Science ®Google Scholar
• Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein–Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery90, 204–213 (1981).
   PubMed Web of Science ®Google Scholar
• Okano M. The evolving therapeutic approaches for Epstein–Barr virus infection in immunocompetent and immunocompromised individuals. Curr. Drug Target Immune Endocr. Metabol. Disord.3, 137–142 (2003).
   PubMedGoogle Scholar
• Okano M. Epstein–Barr virus in patients with immunodeficiency disorders. Biomed. Pharmacother.55, 353–361 (2001).
   PubMed Web of Science ®Google Scholar
• Okano M, Gross TG. A review of Epstein–Barr virus infection in patients with immunodeficiency disorders. Am. J. Med. Sci.319, 392–396 (2000).
   PubMed Web of Science ®Google Scholar
• Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein–Barr virus-specific T lymphocytes (CTL). Blood108, 2942–2949 (2006).
   PubMed Web of Science ®Google Scholar
• Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation80(Suppl.), 272–274 (2005).
   PubMed Web of Science ®Google Scholar
• Beral V, Peterman T, Berkelman R et al. AIDS-associated non-Hodgkin lymphoma. Lancet337, 805–809 (1991).
   PubMed Web of Science ®Google Scholar
• Okano M, Thiele GM, Davis JR, Grierson HL, Purtilo DT. Epstein–Barr virus and human diseases: recent advances in diagnosis. Clin. Microbiol. Rev.1, 300–312 (1988).
   PubMedGoogle Scholar
• Kamel OW, van de Rijn M, Weiss LM et al. Reversible lymphomas associated with Epstein–Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med.328, 1317–1321 (1993).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Tellam JT, Khanna R. Epstein–Barr virus-associated Hodgkin’s lymphoma. Br. J. Haematol.125, 267–281 (2004).
   PubMed Web of Science ®Google Scholar
• Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein–Barr virus infection of diverse human epithelial cells. J. Virol.72, 4371–4378 (1998).
   PubMed Web of Science ®Google Scholar
• Callan MFC, Tan L, Annels N et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein–Barr virus in vivo.J. Exp. Med.187, 1395–1402 (1998).
   PubMed Web of Science ®Google Scholar
• Levitskaya JM, Coram V, Levitsky S et al. Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature375, 385–388 (1995).
   Web of Science ®Google Scholar
• Munz C. Epstein–Barr virus nuclear antigen 1: from immunologically invisible to promising T cell target. J. Exp. Med.199, 1301–1304 (2004).
   PubMed Web of Science ®Google Scholar
• Alfieri C, Birkenbach M, Kieff E. Early events in Epstein–Barr virus infection of human B-lymphocytes. Virology181, 595–608 (1991).
   PubMed Web of Science ®Google Scholar
• Kelly G, Bell A, Rickinson A. Epstein–Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med.8, 1098–1104 (2002).
   PubMed Web of Science ®Google Scholar
• Rigaud S, Fondaneche M-C, Lambert N et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature444, 110–114 (2006).
   PubMed Web of Science ®Google Scholar
• Seemayer TA, Gross TG, Egeler RM et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr. Res.38, 471–478 (1995).
   PubMed Web of Science ®Google Scholar
• Sayos J, Wu C, Morra M et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature395, 462–469 (1998).
   PubMed Web of Science ®Google Scholar
• Coffee AJ, Brooksbank RA, Brandau O et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutation in an SH2-domain-encoding gene. Nat. Genet.20, 195–135 (1998).
   Google Scholar
• Nichols KE, Harkin DT, Levitz S et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Natl Acad. Sci. USA95, 13765–13770 (1998).
   PubMed Web of Science ®Google Scholar
• Okano M, Mizuno F, Aya T, Sakiyama Y, Matsumoto S, Osato T. Epstein–Barr virus hypersensitivity of lymphocytes from patients with ataxia telangiectasia. Int. J. Oncol.2, 1027–1031 (1993).
   PubMed Web of Science ®Google Scholar
• Lu S, Day NE, Degos L et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature346, 470–471 (1990).
   PubMed Web of Science ®Google Scholar
• Armstrong RW, Armstrong MJ, Yi MC, Henderson BE. Salted fish and inhalants as risk factors for nasopharyngeal carcinoma in Malaysian Chinese. Cancer Res.43, 2967–2970 (1983).
   PubMed Web of Science ®Google Scholar
• Osato T, Mizuno F, Imai S et al. African Burkitt’s lymphoma and Epstein–Barr virus-enhancing plant Euphorbia tirucalli. Lancet1(8544), 1257–1258 (1987).
   PubMedGoogle Scholar
• Bar RS, Delor CJ, Clausen KP et al. Fatal infectious mononucleosis in a family. N. Engl. J. Med.290, 363–367 (1974).
   PubMed Web of Science ®Google Scholar
• Parolini S, Bottino C, Falco M et al. X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein–Barr virus-infected cells. J. Exp. Med.192, 337–346 (2000).
   PubMed Web of Science ®Google Scholar
• Sharifi R, Sinclair JC, Gilmour KC et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood103, 3821–3827 (2004).
   PubMed Web of Science ®Google Scholar
• Nichols KE, Hom J, Gong S-Y et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat. Med.11, 340–345 (2005).
   PubMed Web of Science ®Google Scholar
• Okano M, Thiele GM, Kobayashi RH et al. Interferon-γ in a family with X-linked lymphoproliferative syndrome with acute Epstein–Barr virus infection. J. Clin. Immunol.9, 48–54 (1989).
   PubMed Web of Science ®Google Scholar
• Brandau O, Schuster V, Weiss M et al. Epstein–Barr virus negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum. Mol. Genet.8, 2407–2413 (1999).
   PubMed Web of Science ®Google Scholar
• Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science268, 1749–1753 (1995).
   PubMed Web of Science ®Google Scholar
• Berkel AI, Henle W, Henle G et al. Epstein–Barr virus-related antibody patterns in ataxia-telangiectasia. Clin. Exp. Immunol.35, 196–201 (1979).
   PubMed Web of Science ®Google Scholar
• Okano M, Sakiyama Y, Matsumoto S et al. A serological study of Epstein–Barr virus infection in Japanese patients with ataxia telangiectasia. Immunol. Infect. Dis.4, 65–68 (1994).
   Google Scholar
• Reyes C, Abuzaitoum O, De Jong A, Hanson C, Langston C. Epstein–Barr virus-associated smooth muscle tumors in ataxia–telangiectasia: a case report and review. Hum. Pathol.33, 133–136 (2002).
   PubMed Web of Science ®Google Scholar
• Derry JMD, Ochs HD, Franke U. Isolation of a novel gene mutated Wiskott–Aldrich syndrome. Cell78, 635–644 (1994).
   PubMed Web of Science ®Google Scholar
• Vilmer E, Lenoir GM, Virelizier JL, Griscelli C. Epstein–Barr virus serology in immunodeficiency diseases: an attempt to correlate with immune abnormalities in Wiskott–Aldrich and Chediak–Higashi syndromes and ataxia telangiectasia. Clin. Exp. Immunol.55, 249–256 (1984).
   PubMed Web of Science ®Google Scholar
• Sasahara Y, Fujie H, Kumaki S, Ohashi Y, Minegishi M, Tuchiya S. Epstein–Barr virus-associated Hodgkin’s disease in a patient with Wiskott–Aldrich syndrome. Acta Paediatr.90, 1348–1351 (2001).
   PubMed Web of Science ®Google Scholar
• Ozsahin H, Le Deist F, Benkerrou M et al. Bone marrow transplantation in 26 patients with Wiskott–Aldrich syndrome from a single center. J. Pediatr.129, 238–244 (1996).
   PubMed Web of Science ®Google Scholar
• Barbosa MDFS, Nguyen QA, Tcherner VT et al. Identification of the homologous beige and Chediak–Higashi syndrome genes. Nature382, 262–265 (1996).
   PubMed Web of Science ®Google Scholar
• Merino F, Klein G, Henle G et al. Elevated antibody titers to Epstein–Barr virus and low natural killer cell activity in patients with Chediak–Higashi syndrome. Clin. Immunol. Immunopathol.27, 326–339 (1983).
   PubMedGoogle Scholar
• Kinugawa N. Epstein–Barr virus infection in Chediak–Higashi syndrome mimicking acute lymphocytic leukemia. Am. J. Pediatr. Hematol. Oncol.12, 182–186 (1990).
   Google Scholar
• Toita N, Hatano N, Ono S et al. Epstein–Barr virus-associated B-cell lymphoma in a patient with DNA ligase IV (LIG4) syndrome. Am. J. Med. Genet. Part A143A, 742–745 (2007).
   Google Scholar
• Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay. J. Clin. Microbiol.37, 132–136 (1999).
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CYC et al. Use of gene-mediated virus-specific T lymphocytes to control Epstein–Barr virus-related lymphoproliferation. Lancet345, 9–13 (1995).
   PubMed Web of Science ®Google Scholar
• Sivaraman P, Lye WC. Epstein–Barr virus-associated T-cell lymphoma in solid organ transplant recipients. Biomed. Pharmacother.55, 366–368 (2001).
   PubMed Web of Science ®Google Scholar
• Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk. Lymphoma43, 423–426 (2002).
   PubMed Web of Science ®Google Scholar
• Carbone A. AIDS-related non-Hodgkin’s lymphomas: from pathology and molecular pathogenesis to treatment. Hum. Pathol.33, 392–404 (2002).
   PubMed Web of Science ®Google Scholar
• Salloum E, Cooper DL, Howe G et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J. Clin. Oncol.14, 1943–1949 (1996).
   PubMed Web of Science ®Google Scholar
• Mariette X, Cazals-Hatem D, Warsiawski J et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood99, 3909–4015 (2002).
   PubMed Web of Science ®Google Scholar
• Gross TG, Bucuvalas JC, Park JR et al. Low-dose chemotherapy for Epstein–Barr virus-positive post transplant lymphoproliferative disease in children after solid organ transplantation. J. Clin. Oncol.23, 6481–6488 (2005).
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyl M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med.330, 1185–1191 (1994).
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood92, 1549–1555 (1998).
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein–Barr virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet360, 436–442 (2002).
   PubMed Web of Science ®Google Scholar
• Roskrow MA, Suzuki N, Gan Y et al. Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood91, 2925–2934 (1998).
   PubMed Web of Science ®Google Scholar
• Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer100, 1892–1901 (2004).
   PubMed Web of Science ®Google Scholar
• Resnick L, Herbst JS, Ablashi DV et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. J. Am. Med. Assoc.259, 384–388 (1988).
   PubMed Web of Science ®Google Scholar
• Slobod KS, Taylor GH, Sandlund JT, Furth P, Helton KJ, Sixbey JW. Epstein–Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet356(9240), 1493–1494 (2000).
   PubMed Web of Science ®Google Scholar
• Gross TG, Filipovich AH, Conley ME et al. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant.17, 741–744 (1996).
   PubMed Web of Science ®Google Scholar
• Malbran A, Belmonte L, Ruibal-Ares B et al. Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. Blood103, 1625–1631 (2004).
   PubMed Web of Science ®Google Scholar
• Milone MC, Tsai DE, Hodinka RL et al. Treatment of primary Epstein–Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell directed therapy. Blood105, 994–996 (2005).
   PubMed Web of Science ®Google Scholar
• Mischler M, Fleming GM, Shanley TP et al. Epstein–Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit. Pediatrics119(5), e1212–e1218 (2007).
   Google Scholar
• Okano M, Bashir RM, Davis JR, Purtilo DT. Detection of primary Epstein–Barr virus infection in a patient with X-linked lymphoproliferative disease receiving immunoglobulin prophylaxis. Am. J. Hematol.36, 294–296 (1991).
   PubMed Web of Science ®Google Scholar
• Bharadwaj M, Moss DJ. Epstein–Barr virus vaccine: a cytotoxic T-cell-based approach. Expert Rev. Vaccines1, 467–476 (2002).
   PubMedGoogle Scholar